United Therapeutics (UTHR) EPS Estimated At $4.00; Jungheinrich AG (ETR:JUN3) Covered By 6 Bullish Analysts Last Week

October 13, 2017 - By Hazel Jackson

Among 13 analysts covering Jungheinrich (ETR:JUN3), 6 have Buy rating, 0 Sell and 7 Hold. Therefore 46% are positive. Jungheinrich had 47 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was upgraded by Warburg Research to “Buy” on Saturday, April 9. Jefferies upgraded the stock to “Buy” rating in Friday, April 15 report. On Thursday, September 10 the stock rating was upgraded by DZ-Bank AG to “Buy”. BNP Paribas upgraded the shares of JUN3 in report on Friday, April 1 to “Outperform” rating. The firm has “Hold” rating by Baader Wertpapierhandelsbank given on Saturday, August 13. Bankhaus Lampe maintained Jungheinrich AG (ETR:JUN3) rating on Thursday, September 10. Bankhaus Lampe has “Hold” rating and €63 target. Bankhaus Lampe maintained the stock with “Hold” rating in Friday, August 28 report. The stock of Jungheinrich AG (ETR:JUN3) earned “Buy” rating by Landesbank on Wednesday, August 12. Kepler Cheuvreux maintained the shares of JUN3 in report on Thursday, January 19 with “Hold” rating. Bankhaus Lampe maintained Jungheinrich AG (ETR:JUN3) on Tuesday, November 10 with “Hold” rating. See Jungheinrich AG (ETR:JUN3) latest ratings:

Analysts expect United Therapeutics Corporation (NASDAQ:UTHR) to report $4.00 EPS on October, 26.They anticipate $0.37 EPS change or 10.19% from last quarter’s $3.63 EPS. UTHR’s profit would be $173.71M giving it 7.54 P/E if the $4.00 EPS is correct. After having $-1.25 EPS previously, United Therapeutics Corporation’s analysts see -420.00% EPS growth. About shares traded. United Therapeutics Corporation (NASDAQ:UTHR) has risen 9.78% since October 13, 2016 and is uptrending. It has underperformed by 6.92% the S&P500.

Since May 4, 2017, it had 0 buys, and 7 insider sales for $1.09 million activity. On Thursday, May 25 the insider ROTHBLATT MARTINE A sold $151,039.

Among 12 analysts covering United Therapeutics (NASDAQ:UTHR), 2 have Buy rating, 4 Sell and 6 Hold. Therefore 17% are positive. United Therapeutics had 22 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by Jefferies on Tuesday, June 6 with “Sell”. The company was downgraded on Thursday, January 19 by Standpoint Research. Barclays Capital maintained United Therapeutics Corporation (NASDAQ:UTHR) rating on Friday, February 26. Barclays Capital has “Equal-Weight” rating and $145 target. The firm earned “Neutral” rating on Wednesday, June 15 by H.C. Wainwright. The firm earned “Sell” rating on Sunday, August 13 by Jefferies. Oppenheimer maintained it with “Buy” rating and $17500 target in Sunday, July 30 report. The stock of United Therapeutics Corporation (NASDAQ:UTHR) earned “Neutral” rating by Ladenburg Thalmann on Friday, April 29. Jefferies maintained United Therapeutics Corporation (NASDAQ:UTHR) on Thursday, September 14 with “Sell” rating. The rating was maintained by RBC Capital Markets on Wednesday, July 29 with “Sector Perform”. Oppenheimer maintained United Therapeutics Corporation (NASDAQ:UTHR) rating on Tuesday, July 18. Oppenheimer has “Buy” rating and $17500 target.

Investors sentiment decreased to 1.03 in Q2 2017. Its down 0.22, from 1.25 in 2017Q1. It dived, as 54 investors sold United Therapeutics Corporation shares while 106 reduced holdings. 40 funds opened positions while 125 raised stakes. 44.22 million shares or 3.66% less from 45.90 million shares in 2017Q1 were reported. Laurion Cap Mgmt L P owns 156,743 shares. Regentatlantic Capital Lc holds 0.15% or 12,608 shares in its portfolio. Allen Investment Management has 6,434 shares for 0.04% of their portfolio. Sumitomo Mitsui Hldgs stated it has 0.02% in United Therapeutics Corporation (NASDAQ:UTHR). Ny State Common Retirement Fund has invested 0.03% of its portfolio in United Therapeutics Corporation (NASDAQ:UTHR). Retirement Of Alabama invested in 0.06% or 83,291 shares. Maverick Capital Ltd has invested 0.03% in United Therapeutics Corporation (NASDAQ:UTHR). Cwm Limited Liability Com invested in 100 shares. Moreover, Invesco Ltd has 0.01% invested in United Therapeutics Corporation (NASDAQ:UTHR) for 325,441 shares. Thrivent For Lutherans holds 0% of its portfolio in United Therapeutics Corporation (NASDAQ:UTHR) for 9,120 shares. 1,589 are held by Eagle Glob Advisors Ltd Liability. The Pennsylvania-based Ajo L P has invested 0.46% in United Therapeutics Corporation (NASDAQ:UTHR). Toronto Dominion Financial Bank invested in 0% or 552 shares. Orrstown has invested 0.01% of its portfolio in United Therapeutics Corporation (NASDAQ:UTHR). Alliancebernstein L P has 0% invested in United Therapeutics Corporation (NASDAQ:UTHR) for 30,767 shares.

United Therapeutics Corporation is a biotechnology company. The company has market cap of $5.24 billion. The Firm is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. It has a 14.06 P/E ratio. The Firm markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension : Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Jungheinrich AG is a Germany-based holding firm engaged in material handling equipment, warehousing and material flow engineering sectors, as well as in warehousing technology. The company has market cap of 1.84 billion EUR. The Intralogistics segment encompasses the development, production, sale and short-term hire of new material handling equipment and warehousing technology products including logistics systems as well as the sale and short-term hire of used equipment and after-sales services, consisting of maintenance, repair and spare parts. It has a 23.72 P/E ratio. Activities undertaken by the Financial Services segment encompass the pan-European sales financing and usage transfer of material handling equipment and warehousing technology products.

About 44,361 shares traded. Jungheinrich AG (ETR:JUN3) has 0.00% since October 13, 2016 and is . It has underperformed by 16.70% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

>